ES2074563T3 - Procedimiento de preparacion de compuestos y metodo para el tratamiento de la septicemia y/o el choque septico. - Google Patents

Procedimiento de preparacion de compuestos y metodo para el tratamiento de la septicemia y/o el choque septico.

Info

Publication number
ES2074563T3
ES2074563T3 ES90902432T ES90902432T ES2074563T3 ES 2074563 T3 ES2074563 T3 ES 2074563T3 ES 90902432 T ES90902432 T ES 90902432T ES 90902432 T ES90902432 T ES 90902432T ES 2074563 T3 ES2074563 T3 ES 2074563T3
Authority
ES
Spain
Prior art keywords
treatment
gram
septic shock
negative bacteria
septicemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90902432T
Other languages
English (en)
Inventor
Joyce E Lawrence
Michael J Griffith
Melaine Alpern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23160797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2074563(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter International Inc filed Critical Baxter International Inc
Application granted granted Critical
Publication of ES2074563T3 publication Critical patent/ES2074563T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS USADAS PARA EL TRATAMIENTO O PROFILAXIS DE ATAQUES DE BACTERIAS GRAM-NEGATIVAS O DE CHOQUES SEPTICOS, QUE CONTIENEN UNA CANTIDAD SUFICIENTE ANTIBACTERIANA DE INMUNOGLOBULINAS POLICLONICAS CONTRA BACTERIAS GRAM-NEGATIVAS Y UNA CANTIDAD EFECTIVA DE PROTEINA C PARA DISOLVER COAGULOS EN LA SANGRE. LAS COMPOSICIONES PUEDEN CONTENER ADEMAS UNO O MAS COFACTORES DE PROTEINA C Y ANTICUERPOS MONOCLONICOS CONTRA ENDOTOXINAS DE BACTERIAS GRAM-NEGATIVAS. UN METODO PARA EL TRATAMIENTO O PROFILAXIS DE INFECCIONES BACTERIANAS GRAM-NEGATIVAS, O DE CHOQUES SEPTICOS, COMPRENDE LA ADMINISTRACION, JUNTOS O POR SEPARADO, DE UNA CANTIDAD ANTIBACTERIANA EFECTIVA DE INMUNOGLOBULINAS POLICLONICAS CONTRA BACTERIAS GRAM-NEGATIVAS Y DE UNA CANTIDAD EFECTIVA DE PROTEINA C PARA DISOLVER COAGULOS SANGUINEOS. EL METODO PUEDE INCLUIR OPCIONALMENTE ADMINISTRAR UNO O MAS COFACTORES DE PROTEINA C Y ANTICUERPOS MONOCLONICOS CONTRA ENDOTOXINAS DE BACTERIAS GRAM-NEGATIVAS.
ES90902432T 1989-01-24 1990-01-17 Procedimiento de preparacion de compuestos y metodo para el tratamiento de la septicemia y/o el choque septico. Expired - Lifetime ES2074563T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/300,836 US5093117A (en) 1989-01-24 1989-01-24 Compositions and method for the treatment or prophylaxis of sepsis or septic shock

Publications (1)

Publication Number Publication Date
ES2074563T3 true ES2074563T3 (es) 1995-09-16

Family

ID=23160797

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90902432T Expired - Lifetime ES2074563T3 (es) 1989-01-24 1990-01-17 Procedimiento de preparacion de compuestos y metodo para el tratamiento de la septicemia y/o el choque septico.

Country Status (8)

Country Link
US (1) US5093117A (es)
EP (1) EP0406398B1 (es)
JP (1) JP3038006B2 (es)
CA (1) CA1339990C (es)
DE (1) DE69019072T2 (es)
DK (1) DK0406398T3 (es)
ES (1) ES2074563T3 (es)
WO (1) WO1990008556A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1994002172A1 (en) 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
ATE293168T1 (de) * 1993-11-12 2005-04-15 Gilead Sciences Inc Thrombin mutanten
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US20060127387A1 (en) * 1997-04-22 2006-06-15 Zikria Bashir A Compositions based on polysaccharides and protein C and methods of using the same for preventing and treating sepsis and other conditions
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
ZA983496B (en) * 1997-04-28 1999-10-25 Lilly Co Eli Methods for processing activated protein C.
DE19726248C2 (de) * 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Verwendung proteolytischer Enzyme und Rutosid zur Behandlung von septischem Schock
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
CN1324244A (zh) * 1998-10-22 2001-11-28 伊莱利利公司 治疗脓毒症的方法
AU1940800A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Combination therapy for the treatment of sepsis
US6679870B1 (en) 1999-07-23 2004-01-20 Vasca, Inc. Methods and kits for locking and disinfecting implanted catheters
US6685694B2 (en) 1999-07-23 2004-02-03 Vasca, Inc. Methods and kits for locking and disinfecting implanted catheters
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030158111A1 (en) * 1999-10-01 2003-08-21 David Bar-Or Methods and products for oral care
US7592304B2 (en) * 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
EP1289543A2 (en) 2000-05-24 2003-03-12 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
US20050271674A1 (en) * 2001-01-30 2005-12-08 Campbell Joy M Methods and compositions for modulating the immune system of animals
PL211753B1 (pl) * 2001-01-30 2012-06-29 Lauridsen Group Zastosowanie koncentratu antygenowo nie-specyficznych immunoglobulin pochodzących z krwi zwierząt i kompozycja farmaceutyczna zawierająca immunoglobuliny
US20030190314A1 (en) * 2001-01-30 2003-10-09 The Lauridsen Group Methods and compositions of treatment for modulating the immune system of animals
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
US20050143283A1 (en) * 2002-03-08 2005-06-30 Eli Lilly And Company Activated protein c formulations
US7160636B2 (en) 2002-09-13 2007-01-09 Nec Tokin Corporation Ferrite thin film, method of manufacturing the same and electromagnetic noise suppressor using the same
WO2004103294A2 (en) 2003-05-15 2004-12-02 Tanox, Inc. Methods and compositions for the prevention and treatment of sepsis
JP2008523083A (ja) * 2004-12-08 2008-07-03 イムノメディクス， インコーポレイテッド 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
ITFI20070063A1 (it) * 2007-03-15 2008-09-16 Kedrion Spa Concentrato di proteina c contenente proteina s, sua preparazione ed uso.
ES2676422T3 (es) 2012-07-04 2018-07-19 Zz Biotech Llc Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel
ES2890675T3 (es) 2014-04-16 2022-01-21 Zz Biotech Llc APC para uso en el tratamiento de cicatrices cutáneas anormales
PT3131572T (pt) 2014-04-16 2021-09-24 Zz Biotech Llc Análogo de apc para utilização em cicatrização de feridas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
DE3516119A1 (de) * 1985-05-04 1986-11-06 Biotest Pharma GmbH, 6000 Frankfurt Polyvalentes hyperimmunglobulin-praeparat
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S

Also Published As

Publication number Publication date
JP3038006B2 (ja) 2000-05-08
CA1339990C (en) 1998-08-11
EP0406398A1 (en) 1991-01-09
DE69019072T2 (de) 1995-11-30
DE69019072D1 (de) 1995-06-08
EP0406398A4 (en) 1991-07-03
EP0406398B1 (en) 1995-05-03
WO1990008556A1 (en) 1990-08-09
US5093117A (en) 1992-03-03
JPH03503536A (ja) 1991-08-08
DK0406398T3 (da) 1995-07-17

Similar Documents

Publication Publication Date Title
BR9510423A (pt) Formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoìde da mesma, uso da formulação lipossomal antibacteriana
PT759774E (pt) Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
IT1178249B (it) Agente attivo nel trattamento di tossicomania, in particolare da eroina, costituito da una composizione contenente ibogaina
TR199903053T2 (xx) Benzimidazol t�revleri.
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
ATE165976T1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
DK98089A (da) Medikament-lipid-systemer med lav toxicitet
PT90592A (pt) Processo para a preparacao do antibiotico galidermina e de composicoes farmaceuticas e cosmeticas que o contem
ES2161762T3 (es) Polimeros de ionenos como antihelminticos en animales.
EP0869801A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS FOR TREATING MICROBIAL INFECTIONS
DK0737072T3 (da) Anvendelse af simple og konjugerede dekstraner ved fremstilling af et medikament til at forhindre eller nedsætte risikoen f
AR023645A1 (es) Metodo para tratar una infeccion por estafilococos
KR880701734A (ko) 글리코 펩티드 항생물질
DK577181A (da) Polypeptidfraktioner fra muslinger
SE8605044L (sv) Komposition for utvertes bruk
BR9911944A (pt) Proteìna inibidora da quimiotaxia do staphylococcus (proteìna chips) e sua utilização
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
ES508985A0 (es) Procedimiento microbiologico para la obtencion de un nuevo compuesto antibiotico de la cepa streptomyces.
EA200100010A1 (ru) Местное применение оксазолидинонов для трансдермальной доставки
ES2113549T3 (es) Metodo para inhibir la replicacion de vih empleando il-4.
CO4600680A1 (es) Procedimientos para la prevencion de la degradacion de la proteina c
NO20042711L (no) Fremgangsmate for a behandle bakterielle infeksjoner ved anvendelse av gemifloksasin eller et salt derav et betalaktamantibiotikum
FI872459A7 (fi) Farmaseuttinen valmiste bakteeri-infektioiden hoitoon.
BR0014751A (pt) Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 406398

Country of ref document: ES